(March 23, 2022) Phargentis has entered an early license agreement with a major European pharmaceutical company over the third major generic inhaled therapy that Phargentis is developing - an interchangeable version of Fostair® (beclomethasone / formoterol), a best-selling pMDI asthma and COPD treatment with a 2020 turnover of 529 MUSD in Europe. Phargentis CEO Andrea…
Read morePhargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales…
Read more(16 December, 2021) Phargentis has begun clinical development of its capsule based DPI (Dry Powder Inhaler) product containing indacaterol/glycopyrronium (85 mcg/43 mcg) designed to be an early-entry, fully interchangeable generic version of the global COPD treatment Ultibro®Breezhaler®. Sales of the treatment exceed 500 MUSD a year. The news follows the recent announcement of the company’s…
Read more(November 10, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler developed by Phargentis has been launched in Europe. It is the first generic product approved in the EU with precisely the same strength and same delivered dose as Spiriva®Handihaler®, the global first-line treatment for COPD. This generic equivalent has been delivered to the UK, Norway,…
Read more(November 11, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler is the first generic product approved in the EU with the same strength and same delivered dose as Spiriva®Handihaler®, the global first line treatment for COPD – enabling possibility for full reimbursement across the European Union and other key international markets. Developed by Phargentis, it…
Read more